EZH2 and epithelioid sarcoma: These ideas have led to considerable efforts focused on developing efficient and selective epigenetic inhibitors, including one EZH2 inhibitor, tazemetostat (EPZ-6438), which is FDA-approved for follicular lymphoma and epithelioid sarcoma [42].